EHA2024レポート⑦ 注目演題

移植非適応のNDMMに対する1次治療で
イサツキシマブ+VRd療法はVRd療法よりPFSを延長 PHASE 3 STUDY RESULTS OF ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) VERSUS VRD FOR TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (IMROZ) (#S100)

Thierry Facon（University of Lille, and French Academy of Medicine, Department of Hematology, Paris, France）